<p>A. Administration of CLL-specific T-cells <i>in vivo</i> to CLL-engrafted mice resulted in a reduction of splenic B-cell burden from 19.3% in untreated or control-treated mice to 4.5% (p = 0.01) among mice treated with CLL-specific T-cells This was statistically indistinguishable from the 2.8% splenic B-cell content of non-CLL engrafted mice. B. Representative flow cytometry plot of splenic CD19<sup>+</sup> cells. Dashed line/unfilled = isotype control. Thick black line/unfilled = CLL engrafted and treated with CLL-specific effectors. Thin black line/gray filled = CLL engrafted but untreated.</p
